General MedicationsINJECTIONGeneric

EMBOLEX

DIHYDROERGOTAMINE MESYLATE; HEPARIN SODIUM; LIDOCAINE HYDROCHLORIDE

Standard Dose

0.5MG/0.5ML;2,500 UNITS/0.5ML;5.33MG/0.5ML

Max Dose

Refer to approved labeling

Primary Use

Marketing status: Discontinued

Summary

Approval overview EMBOLEX is listed in Drugs@FDA under application 018885 (NDA).

Marketing status: Discontinued Active ingredient DIHYDROERGOTAMINE MESYLATE; HEPARIN SODIUM; LIDOCAINE HYDROCHLORIDE Form and strength INJECTABLE;INJECTION - 0.5MG/0.5ML;2,500 UNITS/0.5ML;5.33MG/0.5ML Sponsor NOVARTIS Submission history See approval history documents.

Structured Monograph

Clinical summary

Approval overview EMBOLEX is listed in Drugs@FDA under application 018885 (NDA). Marketing status: Discontinued Active ingredient DIHYDROERGOTAMINE MESYLATE; HEPARIN SODIUM; LIDOCAINE HYDROCHLORIDE Form and strength INJECTABLE;INJECTION - 0.5MG/0.5ML;2,500 UNITS/0.5ML;5.33MG/0.5ML Sponsor NOVARTIS Submission history See approval history documents.

Monitoring

• Marketing status: Discontinued

Interaction Notes

No interaction notes stored yet.